Vaxart (VXRT) to Release Quarterly Earnings on Thursday

Vaxart (NASDAQ:VXRT) is set to announce its earnings results after the market closes on Thursday, August 8th. Analysts expect the company to announce earnings of $0.03 per share for the quarter.

Vaxart (NASDAQ:VXRT) last posted its quarterly earnings data on Monday, May 13th. The biotechnology company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.02. The company had revenue of $2.18 million for the quarter. Vaxart had a negative net margin of 920.00% and a negative return on equity of 121.06%. On average, analysts expect Vaxart to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Vaxart Stock Down 5.9 %

Shares of NASDAQ VXRT opened at $0.62 on Friday. The firm has a market cap of $110.01 million, a PE ratio of -1.17 and a beta of 0.65. Vaxart has a 12-month low of $0.52 and a 12-month high of $1.54. The company’s fifty day simple moving average is $0.71 and its 200 day simple moving average is $0.92.

About Vaxart

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.